Numerous therapeutic advancements have been achieved in the topic of GC during the past two decades, including CAR T‐cell therapy and the disclosing of new molecular targets like CLDN18.2, human epidermal growth factor receptor 2 (Her2), and fibroblast growth factor receptor 2b (FGFR2b) [2, 3, 4]. Here, ERBB2 is linked to gastric cancer.